Literature DB >> 24129286

Evaluating the quality of antimicrobial prescribing: is standardisation possible?

Pilar Retamar1, M Luisa Martín, José Molina, Alfonso del Arco.   

Abstract

The quality of antimicrobial prescribing refers to the optimal way to use antibiotics in regard to their benefits, safety (e.g., resistance generation and toxicity) and cost. Evaluating the quality of antimicrobial prescribing in a way that focuses not only on reducing antimicrobial consumption but also on using them in a more optimal way allows us to understand patterns of use and to identify targets for intervention. The lack of standardisation is the primary problem to be addressed when planning an evaluation of antimicrobial prescribing. There is little information specifically describing an evaluation methodology. Information related to prescription evaluation can be obtained from the guidelines of Antimicrobial Stewardship Programs (ASPs) and from local and international experience. The criteria used to evaluate the quality of prescription should include the indication for antimicrobial therapy, the timeliness of initiation, the correct antibiotic choice (according to local guidelines), the dosing, the duration, the route of administration and the time at which to switch to oral administration. A locally developed guideline on antimicrobial therapy should preferably be the gold standard by which to evaluate the appropriatenes of prescriptions. Various approaches used to carry out the evaluations have been described in the literature. Repeated point-prevalence surveys (PPS) have been proven to be effective in identifying targets for quality improvement. Continuous prospective monitoring allows the identification of more precise intervention points at different times during prescription. The design of the study chosen to perform the evaluation should be adapted according to the resources available in each centre. Evaluating the quality of antimicrobial prescribing should be the first step to designing ASPs, as well as to evaluating their impact and the changes in prescribing trends over time.
Copyright © 2013 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Antibiótico; Antimicrobial; Encuestas de prevalencia; Evaluación; Evaluation; Guideline; Guía; Optimización; Prescribing; Prescripción; Prevalence surveys; Stewardship

Mesh:

Substances:

Year:  2013        PMID: 24129286     DOI: 10.1016/S0213-005X(13)70129-0

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  4 in total

1.  Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.

Authors:  P Garcinuño; M Santibañez; L Gimeno; A Sánchez-Bautista; J Coy; J Sánchez-Paya; V Boix; E Merino; J Portilla; J C Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-09       Impact factor: 3.267

2.  Antibiotic use in a tertiary healthcare facility in Ghana: a point prevalence survey.

Authors:  Appiah-Korang Labi; Noah Obeng-Nkrumah; Edmund Tetteh Nartey; Stephanie Bjerrum; Nii Armah Adu-Aryee; Yaw Adjei Ofori-Adjei; Alfred E Yawson; Mercy J Newman
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-26       Impact factor: 4.887

3.  Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure.

Authors:  Annelie A Monnier; Barry I Eisenstein; Marlies E Hulscher; Inge C Gyssens
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

4.  Longitudinal point prevalence survey of antibacterial use in Northern Ireland using the European Surveillance of Antimicrobial Consumption (ESAC) PPS and Global-PPS tool.

Authors:  G M Al-Taani; M Scott; D Farren; F Gilmore; B Mccullagh; C Hibberd; A Mccorry; A Versporten; H Goossens; P Zarb; M A Aldeyab
Journal:  Epidemiol Infect       Date:  2018-04-25       Impact factor: 4.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.